The role of bone in phosphate metabolism

Molecular and Cellular Endocrinology

Volumn 310, Issue 1-2, 2009, Pages 63-70

  Fukumoto, Seiji ^a  

^a UNIVERSITY OF TOKYO HOSPITAL   (Japan)

Author keywords

FGF23; Hyperphosphatemia; Hypophosphatemia; Osteomalacia; Rickets

Indexed keywords

DENTIN MATRIX PROTEIN 1; FIBROBLAST GROWTH FACTOR 23; FIBROBLAST GROWTH FACTOR RECEPTOR; KLOTHO PROTEIN; PARATHYROID HORMONE; PHOSPHATE;

ALBRIGHT SYNDROME; BONE; GENE MUTATION; HUMAN; HYPERPHOSPHATEMIA; HYPOPHOSPHATEMIA; HYPOPHOSPHATEMIC RICKETS; KIDNEY TUBULE ABSORPTION; NONHUMAN; OSTEOCYTE; OSTEOMALACIA; PARATHYROID HORMONE RELEASE; PHOSPHATE BLOOD LEVEL; PHOSPHATE METABOLISM; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; REVIEW; TUMOR CALCINOSIS;

ANIMALS; BONE AND BONES; FIBROBLAST GROWTH FACTORS; HYPERPHOSPHATEMIA; HYPOPHOSPHATEMIA; PHOSPHATES;

EID: 69249231022     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2008.08.031     Document Type: Review

References (103)

1. ADHR Consortium. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat. Genet. 26 (2000) 345-348
2. Antoniucci D.M., Yamashita T., and Portale A.A. Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. J. Clin. Endocrinol. Metab. 91 (2006) 3144-3149
3. Aono Y., Shimada T., Yamazaki Y., Hino R., Takeuchi Y., Fujita T., Fukumoto S., Nagano N., and Yamashita T. The neutralization of FGF-23 ameliorates hypophosphatemia and rickets in Hyp mice. J. Bone Miner. Res. 18 (2003) S16
4. Araya K., Fukumoto S., Backenroth R., Takeuchi Y., Nakayama K., Ito N., Yoshii N., Yamazaki Y., Yamashita T., Silver J., Igarashi T., and Fujita T. A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis. J. Clin. Endocrinol. Metab. 90 (2005) 5523-5527
5. Barbieri A.M., Filopanti M., Bua G., and Beck-Peccoz P. Two novel nonsense mutations in GALNT3 gene are responsible for familial tumoral calcinosis. J. Hum. Genet. 52 (2007) 464-468
6. Beck L., Soumounou Y., Martel J., Krishnamurthy G., Gauthier C., Goodyer C.G., and Tenenhouse H.S. Pex/PEX tissue distribution and evidence for a deletion in the 3′ region of the Pex gene in X-linked hypophosphatemic mice. J. Clin. Invest. 99 (1997) 1200-1209
7. Beck L., Karaplis A.C., Amizuka N., Hewson A.S., Ozawa H., and Tenenhouse H.S. Targeted inactivation of Npt2 in mice leads to severe renal phosphate wasting, hypercalciuria, and skeletal abnormalities. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 5372-5377
8. Ben-Dov I.Z., Galitzer H., Lavi-Moshayoff V., Goetz R., Kuro-o M., Mohammadi M., Sirkis R., Naveh-Many T., and Silver J. The parathyroid is a target organ for FGF23 in rats. J. Clin. Invest. 117 (2007) 4003-4008
9. Benet-Pages A., Lorenz-Depiereux B., Zischka H., White K.E., Econs M.J., and Strom T.M. FGF23 is processed by proprotein convertases but not by PHEX. Bone 35 (2004) 455-462
10. Benet-Pages A., Orlik P., Strom T.M., and Lorenz-Depiereux B. An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum. Mol. Genet. 14 (2005) 385-390
11. Berndt T., Craig T.A., Bowe A.E., Vassiliadis J., Reczek D., Finnegan R., Jan De Beur S.M., Schiavi S.C., and Kumar R. Secreted frizzled-related protein 4 is a potent tumor-derived phosphaturic agent. J. Clin. Invest. 112 (2003) 785-794
12. Bianchetti L., Oudet C., and Poch O. M13 endopeptidases: new conserved motifs correlated with structure, and simultaneous phylogenetic occurrence of PHEX and the bony fish. Proteins 47 (2002) 481-488
13. Brown E.M., and MacLeod R.J. Extracellular calcium sensing and extracellular calcium signaling. Physiol. Rev. 81 (2001) 239-297
14. Burnett S.M., Gunawardene S.C., Bringhurst F.R., Juppner H., Lee H., and Finkelstein J.S. Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J. Bone Miner. Res. 21 (2006) 1187-1196
15. Campagnoli M.F., Pucci A., Garelli E., Carando A., Defilippi C., Lala R., Ingrosso G., Dianzani I., Forni M., and Ramenghi U. Familial tumoral calcinosis and testicular microlithiasis associated with a new mutation of GALNT3 in a white family. J. Clin. Pathol. 59 (2006) 440-442
16. Carpenter T.O., Ellis B.K., Insogna K.L., Philbrick W.M., Sterpka J., and Shimkets R. Fibroblast growth factor 7: an inhibitor of phosphate transport derived from oncogenic osteomalacia-causing tumors. J. Clin. Endocrinol. Metab. 90 (2005) 1012-1020
17. Chefetz I., Heller R., Galli-Tsinopoulou A., Richard G., Wollnik B., Indelman M., Koerber F., Topaz O., Bergman R., Sprecher E., and Schoenau E. A novel homozygous missense mutation in FGF23 causes familial tumoral calcinosis associated with disseminated visceral calcification. Hum. Genet. 118 (2005) 261-266
18. Econs M.J., and Drezner M.K. Tumor-induced osteomalacia: unveiling a new hormone. N. Engl. J. Med. 330 (1994) 1679-1681
19. Endo I., Fukumoto S., Ozono K., Namba N., Tanaka H., Inoue D., Minagawa M., Sugimoto T., Yamauchi M., Michigami T., and Matsumoto T. Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement. Bone 42 (2008) 1235-1239
20. Feng J.Q., Ward L.M., Liu S., Lu Y., Xie Y., Yuan B., Yu X., Rauch F., Davis S.I., Zhang S., Rios H., Drezner M.K., Quarles L.D., Bonewald L.F., and White K.E. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat. Genet. 38 (2006) 1310-1315
21. Ferrari S.L., Bonjour J.P., and Rizzoli R. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J. Clin. Endocrinol. Metab. 90 (2005) 1519-1524
22. Folpe A.L., Fanburg-Smith J.C., Billings S.D., Bisceglia M., Bertoni F., Cho J.Y., Econs M.J., Inwards C.Y., Jan de Beur S.M., Mentzel T., Montgomery E., Michal M., Miettinen M., Mills S.E., Reith J.D., O'Connell J.X., Rosenberg A.E., Rubin B.P., Sweet D.E., Vinh T.N., Wold L.E., Wehrli B.M., White K.E., Zaino R.J., and Weiss S.W. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am. J. Surg. Pathol. 28 (2004) 1-30
23. Frishberg Y., Ito N., Rinat C., Yamazaki Y., Feinstein S., Urakawa I., Navon-Elkan P., Becker-Cohen R., Yamashita T., Araya K., Igarashi T., Fujita T., and Fukumoto S. Hyperostosis-hyperphosphatemia syndrome: a congenital disorder of O-glycosylation associated with augmented processing of fibroblast growth factor 23. J. Bone Miner. Res. 22 (2007) 235-242
24. Fukumoto S., Takeuchi Y., Nagano A., and Fujita T. Diagnostic utility of magnetic resonance imaging skeletal survey in a patient with oncogenic osteomalacia: a case report. Bone 25 (1999) 375-377
25. Garringer H.J., Mortazavi S.M., Esteghamat F., Malekpour M., Boztepe H., Tanakol R., Davis S.I., and White K.E. Two novel GALNT3 mutations in familial tumoral calcinosis. Am. J. Med. Genet. A 143 (2007) 2390-2396
26. Goetz R., Beenken A., Ibrahimi O.A., Kalinina J., Olsen S.K., Eliseenkova A.V., Xu C., Neubert T.A., Zhang F., Linhardt R.J., Yu X., White K.E., Inagaki T., Kliewer S.A., Yamamoto M., Kurosu H., Ogawa Y., Kuro-o M., Lanske B., Razzaque M.S., and Mohammadi M. Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol. Cell. Biol. 27 (2007) 3417-3428
27. Gupta A., Winer K., Econs M.J., Marx S.J., and Collins M.T. FGF-23 is elevated by chronic hyperphosphatemia. J. Clin. Endocrinol. Metab. 89 (2004) 4489-4492
28. Ichikawa S., Lyles K.W., and Econs M.J. A novel GALNT3 mutation in a pseudoautosomal dominant form of tumoral calcinosis: evidence that the disorder is autosomal recessive. J. Clin. Endocrinol. Metab. 90 (2005) 2420-2423
29. Ichikawa S., Imel E.A., Sorenson A.H., Severe R., Knudson P., Harris G.J., Shaker J.L., and Econs M.J. Tumoral calcinosis presenting with eyelid calcifications due to novel missense mutations in the glycosyl transferase domain of the GALNT3 gene. J. Clin. Endocrinol. Metab. 91 (2006) 4472-4475
30. Ichikawa S., Guigonis V., Imel E.A., Courouble M., Heissat S., Henley J.D., Sorenson A.H., Petit B., Lienhardt A., and Econs M.J. Novel GALNT3 mutations causing hyperostosis-hyperphosphatemia syndrome result in low intact fibroblast growth factor 23 concentrations. J. Clin. Endocrinol. Metab. 92 (2007) 1943-1947
31. Ichikawa S., Imel E.A., Kreiter M.L., Yu X., Mackenzie D.S., Sorenson A.H., Goetz R., Mohammadi M., White K.E., and Econs M.J. A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. J. Clin. Invest. 117 (2007) 2684-2691
32. Imanishi Y., Inaba M., Nakatsuka K., Nagasue K., Okuno S., Yoshihara A., Miura M., Miyauchi A., Kobayashi K., Miki T., Shoji T., Ishimura E., and Nishizawa Y. FGF-23 in patients with end-stage renal disease on hemodialysis. Kidney Int. 65 (2004) 1943-1946
33. Imel E.A., Peacock M., Pitukcheewanont P., Heller H.J., Ward L.M., Shulman D., Kassem M., Rackoff P., Zimering M., Dalkin A., Drobny E., Colussi G., Shaker J.L., Hoogendoorn E.H., Hui S.L., and Econs M.J. Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia. J. Clin. Endocrinol. Metab. 91 (2006) 2055-2061
34. Imel E.A., Hui S.L., and Econs M.J. FGF23 concentrations vary with disease status in autosomal dominant hypophosphatemic rickets. J. Bone Miner. Res. 22 (2007) 520-526
35. Imura A., Tsuji Y., Murata M., Maeda R., Kubota K., Iwano A., Obuse C., Togashi K., Tominaga M., Kita N., Tomiyama K., Iijima J., Nabeshima Y., Fujioka M., Asato R., Tanaka S., Kojima K., Ito J., Nozaki K., Hashimoto N., Ito T., Nishio T., Uchiyama T., Fujimori T., and Nabeshima Y. Alpha-Klotho as a regulator of calcium homeostasis. Science 316 (2007) 1615-1618
36. Inagaki T., Choi M., Moschetta A., Peng L., Cummins C.L., McDonald J.G., Luo G., Jones S.A., Goodwin B., Richardson J.A., Gerard R.D., Repa J.J., Mangelsdorf D.J., and Kliewer S.A. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab. 2 (2005) 217-225
37. Ito N., Fukumoto S., Takeuchi Y., Yasuda T., Hasegawa Y., Takemoto F., Tajima T., Dobashi K., Yamazaki Y., Yamashita T., and Fujita T. Comparison of two assays for fibroblast growth factor (FGF)-23. J. Bone Miner. Metab. 23 (2005) 435-440
38. Ito N., Fukumoto S., Takeuchi Y., Takeda S., Suzuki H., Yamashita T., and Fujita T. Effect of acute changes of serum phosphate on fibroblast growth factor (FGF)23 levels in humans. J. Bone Miner. Metab. 25 (2007) 419-422
39. Ito S., Kinoshita S., Shiraishi N., Nakagawa S., Sekine S., Fujimori T., and Nabeshima Y.I. Molecular cloning and expression analyses of mouse betaklotho, which encodes a novel Klotho family protein. Mech. Dev. 98 (2000) 115-119
40. Ito S., Fujimori T., Furuya A., Satoh J., Nabeshima Y., and Nabeshima Y. Impaired negative feedback suppression of bile acid synthesis in mice lacking betaKlotho. J. Clin. Invest. 115 (2005) 2202-2208
41. Itoh N., and Ornitz D.M. Evolution of the Fgf and Fgfr gene families. Trends Genet. 20 (2004) 563-569
42. Itoh N., and Ornitz D.M. Functional evolutionary history of the mouse Fgf gene family. Dev. Dyn. 237 (2008) 18-27
43. Jan de Beur S.M., Streeten E.A., Civelek A.C., McCarthy E.F., Uribe L., Marx S.J., Onobrakpeya O., Raisz L.G., Watts N.B., Sharon M., and Levine M.A. Localisation of mesenchymal tumours by somatostatin receptor imaging. Lancet 359 (2002) 761-763
44. Jonsson K.B., Zahradnik R., Larsson T., White K.E., Sugimoto T., Imanishi Y., Yamamoto T., Hampson G., Koshiyama H., Ljunggren O., Oba K., Yang I.M., Miyauchi A., Econs M.J., Lavigne J., and Juppner H. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N. Engl. J. Med. 348 (2003) 1656-1663
45. Kato K., Jeanneau C., Tarp M.A., Benet-Pages A., Lorenz-Depiereux B., Bennett E.P., Mandel U., Strom T.M., and Clausen H. Polypeptide GalNAc-transferase T3 and familial tumoral calcinosis. Secretion of fibroblast growth factor 23 requires O-glycosylation. J. Biol. Chem. 281 (2006) 18370-18377
46. Kharitonenkov A., Shiyanova T.L., Koester A., Ford A.M., Micanovic R., Galbreath E.J., Sandusky G.E., Hammond L.J., Moyers J.S., Owens R.A., Gromada J., Brozinick J.T., Hawkins E.D., Wroblewski V.J., Li D.S., Mehrbod F., Jaskunas S.R., and Shanafelt A.B. FGF-21 as a novel metabolic regulator. J. Clin. Invest. 115 (2005) 1627-1635
47. Kharitonenkov A., Dunbar J.D., Bina H.A., Bright S., Moyers J.S., Zhang C., Ding L., Micanovic R., Mehrbod S.F., Knierman M.D., Hale J.E., Coskun T., and Shanafelt A.B. FGF-21/FGF-21 receptor interaction and activation is determined by betaKlotho. J. Cell. Physiol. 215 (2008) 1-7
48. Khosravi A., Cutler C.M., Kelly M.H., Chang R., Royal R.E., Sherry R.M., Wodajo F.M., Fedarko N.S., and Collins M.T. Determination of the elimination half-life of fibroblast growth factor-23. J. Clin. Endocrinol. Metab. 92 (2007) 2374-2377
49. Kolek O.I., Hines E.R., Jones M.D., LeSueur L.K., Lipko M.A., Kiela P.R., Collins J.F., Haussler M.R., and Ghishan F.K. 1alpha,25-Dihydroxyvitamin D3 upregulates FGF23 gene expression in bone: the final link in a renal-gastrointestinal-skeletal axis that controls phosphate transport. Am. J. Physiol. Gastrointest. Liver Physiol. 289 (2005) G1036-G1042
50. Krajisnik T., Bjorklund P., Marsell R., Ljunggren O., Akerstrom G., Jonsson K.B., Westin G., and Larsson T.E. Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J. Endocrinol. 195 (2007) 125-131
51. Kuro-o M., Matsumura Y., Aizawa H., Kawaguchi H., Suga T., Utsugi T., Ohyama Y., Kurabayashi M., Kaname T., Kume E., Iwasaki H., Iida A., Shiraki-Iida T., Nishikawa S., Nagai R., and Nabeshima Y.I. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 390 (1997) 45-51
52. Kurosu H., Ogawa Y., Miyoshi M., Yamamoto M., Nandi A., Rosenblatt K.P., Baum M.G., Schiavi S., Hu M.C., Moe O.W., and Kuro-o M. Regulation of fibroblast growth factor-23 signaling by klotho. J. Biol. Chem. 281 (2006) 6120-6123
53. Kurosu H., Choi M., Ogawa Y., Dickson A.S., Goetz R., Eliseenkova A.V., Mohammadi M., Rosenblatt K.P., Kliewer S.A., and Kuro O.M. Tissue-specific expression of betaKLOTHO and fibroblast growth factor receptor isoforms determines metabolic activity of FGF19 and FGF21. J. Biol. Chem. 282 (2007) 26687-26695
54. Larsson T., Nisbeth U., Ljunggren O., Juppner H., and Jonsson K.B. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int. 64 (2003) 2272-2279
55. Larsson T., Davis S.I., Garringer H.J., Mooney S.D., Draman M.S., Cullen M.J., and White K.E. Fibroblast growth factor-23 mutants causing familial tumoral calcinosis are differentially processed. Endocrinology 146 (2005) 3883-3891
56. Lin B.C., Wang M., Blackmore C., and Desnoyers L.R. Liver-specific activities of FGF19 require Klotho beta. J. Biol. Chem. 282 (2007) 27277-27284
57. Liu S., Guo R., Simpson L.G., Xiao Z.S., Burnham C.E., and Quarles L.D. Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J. Biol. Chem. 278 (2003) 37419-37426
58. Liu S., Tang W., Zhou J., Stubbs J.R., Luo Q., Pi M., and Quarles L.D. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J. Am. Soc. Nephrol. 17 (2006) 1305-1315
59. Liu S.G., Tang W., Zhou J.P., Vierthaler L., and Quarles L.D. Distinct roles for intrinsic osteocyte abnormalities and systemic factors in regulation of FGF23 and bone mineralization in Hyp mice. Am. J. Physiol. Endocrinol. Metab. 293 (2007) E1636-E1644
60. Liu S., Zhou J., Tang W., Menard R., Feng J.Q., and Quarles L.D. Pathogenic role of Fgf23 in Dmp1 null mice. Am. J. Physiol. Endocrinol. Metab. 295 (2008) E254-E261
61. Lorenz-Depiereux B., Bastepe M., Benet-Pages A., Amyere M., Wagenstaller J., Muller-Barth U., Badenhoop K., Kaiser S.M., Rittmaster R.S., Shlossberg A.H., Olivares J.L., Loris C., Ramos F.J., Glorieux F., Vikkula M., Juppner H., and Strom T.M. DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat. Genet. 38 (2006) 1248-1250
62. Lotscher M., Scarpetta Y., Levi M., Halaihel N., Wang H., Zajicek H.K., Biber J., Murer H., and Kaissling B. Rapid downregulation of rat renal Na/P(i) cotransporter in response to parathyroid hormone involves microtubule rearrangement. J. Clin. Invest. 104 (1999) 483-494
63. Lyles K.W., Halsey D.L., Friedman N.E., and Lobaugh B. Correlations of serum concentrations of 1,25-dihydroxyvitamin D, phosphorus, and parathyroid hormone in tumoral calcinosis. J. Clin. Endocrinol. Metab. 67 (1988) 88-92
64. Meyer Jr. R.A., Meyer M.H., and Gray R.W. Parabiosis suggests a humoral factor is involved in X-linked hypophosphatemia in mice. J. Bone Miner. Res. 4 (1989) 493-500
65. Mirams M., Robinson B.G., Mason R.S., and Nelson A.E. Bone as a source of FGF23: regulation by phosphate?. Bone 35 (2004) 1192-1199
66. Morgan J.M., Hawley W.L., Chenoweth A.I., Retan W.J., and Diethelm A.G. Renal transplantation in hypophosphatemia with vitamin D-resistant rickets. Arch. Intern. Med. 134 (1974) 549-552
67. Nasu T., Kurisu S., Matsuno S., Tatsumi K., Kakimoto T., Kobayashi M., Nakano Y., Wakasaki H., Furuta H., Nishi M., Sasaki H., Suzuki H., Ito N., Fukumoto S., and Nanjo K. Tumor-induced hypophosphatemic osteomalacia diagnosed by the combinatory procedures of magnetic resonance imaging and venous sampling for FGF23. Intern. Med. 47 (2008) 957-961
68. Nesbitt T., Coffman T.M., Griffiths R., and Drezner M.K. Crosstransplantation of kidneys in normal and Hyp mice. Evidence that the Hyp mouse phenotype is unrelated to an intrinsic renal defect. J. Clin. Invest. 89 (1992) 1453-1459
69. Ogawa Y., Kurosu H., Yamamoto M., Nandi A., Rosenblatt K.P., Goetz R., Eliseenkova A.V., Mohammadi M., and Kuro-o M. BetaKlotho is required for metabolic activity of fibroblast growth factor 21. Proc. Natl. Acad. Sci. U.S.A. 104 (2007) 7432-7437
70. Ogura E., Kageyama K., Fukumoto S., Yagihashi N., Fukuda Y., Kikuchi T., Masuda M., and Suda T. Development of tumor-induced osteomalacia in a subcutaneous tumor, defined by venous blood sampling of fibroblast growth factor-23. Intern. Med. 47 (2008) 637-641
71. Olauson H., Krajisnik T., Larsson C., Lindberg B., and Larsson T.E. A novel missense mutation in GALNT3 causing hyperostosis-hyperphosphataemia syndrome. Eur. J. Endocrinol. 158 (2008) 929-934
72. Perwad F., Azam N., Zhang M.Y., Yamashita T., Tenenhouse H.S., and Portale A.A. Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1,25-dihydroxyvitamin D metabolism in mice. Endocrinology 146 (2005) 5358-5364
73. Riminucci M., Collins M.T., Fedarko N.S., Cherman N., Corsi A., White K.E., Waguespack S., Gupta A., Hannon T., Econs M.J., Bianco P., and Gehron Robey P. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J. Clin. Invest. 112 (2003) 683-692
74. Rowe P.S., Kumagai Y., Gutierrez G., Garrett I.R., Blacher R., Rosen D., Cundy J., Navvab S., Chen D., Drezner M.K., Quarles L.D., and Mundy G.R. MEPE has the properties of an osteoblastic phosphatonin and minhibin. Bone 34 (2004) 303-319
75. Ruchon A.F., Tenenhouse H.S., Marcinkiewicz M., Siegfried G., Aubin J.E., DesGroseillers L., Crine P., and Boileau G. Developmental expression and tissue distribution of Phex protein: effect of the Hyp mutation and relationship to bone markers. J. Bone Miner. Res. 15 (2000) 1440-1450
76. Saito H., Maeda A., Ohtomo S., Hirata M., Kusano K., Kato S., Ogata E., Segawa H., Miyamoto K., and Fukushima N. Circulating FGF-23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo. J. Biol. Chem. 280 (2005) 2543-2549
77. Segawa H., Kaneko I., Takahashi A., Kuwahata M., Ito M., Ohkido I., Tatsumi S., and Miyamoto K. Growth-related renal type II Na/Pi cotransporter. J. Biol. Chem. 277 (2002) 19665-19672
78. Segawa H., Yamanaka S., Onitsuka A., Tomoe Y., Kuwahata M., Ito M., Taketani Y., and Miyamoto K. Parathyroid hormone-dependent endocytosis of renal type IIc Na-Pi cotransporter. Am. J. Physiol. Renal Physiol. 292 (2007) F395-F403
79. Shigematsu T., Kazama J.J., Yamashita T., Fukumoto S., Hosoya T., Gejyo F., and Fukagawa M. Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am. J. Kidney Dis. 44 (2004) 250-256
80. Shimada T., Mizutani S., Muto T., Yoneya T., Hino R., Takeda S., Takeuchi Y., Fujita T., Fukumoto S., and Yamashita T. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 6500-6505
81. Shimada T., Muto T., Urakawa I., Yoneya T., Yamazaki Y., Okawa K., Takeuchi Y., Fujita T., Fukumoto S., and Yamashita T. Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology 143 (2002) 3179-3182
82. Shimada T., Hasegawa H., Yamazaki Y., Muto T., Hino R., Takeuchi Y., Fujita T., Nakahara K., Fukumoto S., and Yamashita T. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J. Bone Miner. Res. 19 (2004) 429-435
83. Shimada T., Kakitani M., Yamazaki Y., Hasegawa H., Takeuchi Y., Fujita T., Fukumoto S., Tomizuka K., and Yamashita T. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J. Clin. Invest. 113 (2004) 561-568
84. Sitara D., Razzaque M.S., Hesse M., Yoganathan S., Taguchi T., Erben R.G., Juppner H., and Lanske B. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol. 23 (2004) 421-432
85. Specktor P., Cooper J.G., Indelman M., and Sprecher E. Hyperphosphatemic familial tumoral calcinosis caused by a mutation in GALNT3 in a European kindred. J. Hum. Genet. 51 (2006) 487-490
86. Suzuki M., Uehara Y., Motomura-Matsuzaka K., Oki J., Koyama Y., Kimura M., Asada M., Komi-Kuramochi A., Oka S., and Imamura T. betaKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c. Mol. Endocrinol. 22 (2008) 1006-1014
87. Takeuchi Y., Suzuki H., Ogura S., Imai R., Yamazaki Y., Yamashita T., Miyamoto Y., Okazaki H., Nakamura K., Nakahara K., Fukumoto S., and Fujita T. Venous sampling for fibroblast growth factor-23 confirms preoperative diagnosis of tumor-induced osteomalacia. J. Clin. Endocrinol. Metab. 89 (2004) 3979-3982
88. Ten Hagen K.G., Fritz T.A., and Tabak L.A. All in the family: the UDP-GalNAc: polypeptide N-acetylgalactosaminyltransferases. Glycobiology 13 (2003) 1R-16R
89. The HYP Consortium. A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. Nat. Genet. 11 (1995) 130-136
90. Topaz O., Shurman D.L., Bergman R., Indelman M., Ratajczak P., Mizrachi M., Khamaysi Z., Behar D., Petronius D., Friedman V., Zelikovic I., Raimer S., Metzker A., Richard G., and Sprecher E. Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis. Nat. Genet. 36 (2004) 579-581
91. Tsujikawa H., Kurotaki Y., Fujimori T., Fukuda K., and Nabeshima Y. Klotho, a gene related to a syndrome resembling human premature aging, functions in a negative regulatory circuit of vitamin D endocrine system. Mol. Endocrinol. 17 (2003) 2393-2403
92. Urakawa I., Yamazaki Y., Shimada T., Iijima K., Hasegawa H., Okawa K., Fujita T., Fukumoto S., and Yamashita T. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444 (2006) 770-774
93. van Boekel G., Ruinemans-Koerts J., Joosten F., Dijkhuizen P., van Sorge A., and de Boer H. Tumor producing fibroblast growth factor 23 localized by two-staged venous sampling. Eur. J. Endocrinol. 158 (2008) 431-437
94. Weber T.J., Liu S., Indridason O.S., and Quarles L.D. Serum FGF23 levels in normal and disordered phosphorus homeostasis. J. Bone Miner. Res. 18 (2003) 1227-1234
95. Westerberg P.A., Olauson H., Toss G., Wikstrom B., Morales O., Linde T., Jonsson K., Ljunggren O., and Larsson T.E. Preoperative tumor localization by means of venous sampling for fibroblast growth factor-23 in a patient with tumor-induced osteomalacia. Endocr. Pract. 14 (2008) 362-367
96. White K.E., Carn G., Lorenz-Depiereux B., Benet-Pages A., Strom T.M., and Econs M.J. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int. 60 (2001) 2079-2086
97. White K.E., Jonsson K.B., Carn G., Hampson G., Spector T.D., Mannstadt M., Lorenz-Depiereux B., Miyauchi A., Yang I.M., Ljunggren O., Meitinger T., Strom T.M., Juppner H., and Econs M.J. The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting. J. Clin. Endocrinol. Metab. 86 (2001) 497-500
98. Wu X., Ge H., Gupte J., Weiszmann J., Shimamoto G., Stevens J., Hawkins N., Lemon B., Shen W., Xu J., Veniant M.M., Li Y.S., Lindberg R., Chen J.L., Tian H., and Li Y. Co-receptor requirements for fibroblast growth factor-19 signaling. J. Biol. Chem. 282 (2007) 29069-29072
99. Yamashita T., Yoshioka M., and Itoh N. Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem. Biophys. Res. Commun. 277 (2000) 494-498
100. Yamazaki Y., Okazaki R., Shibata M., Hasegawa Y., Satoh K., Tajima T., Takeuchi Y., Fujita T., Nakahara K., Yamashita T., and Fukumoto S. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J. Clin. Endocrinol. Metab. 87 (2002) 4957-4960
101. Yoshida T., Fujimori T., and Nabeshima Y. Mediation of unusually high concentrations of 1,25-dihydroxyvitamin D in homozygous klotho mutant mice by increased expression of renal 1alpha-hydroxylase gene. Endocrinology 143 (2002) 683-689
102. Yoshiko Y., Wang H., Minamizaki T., Ijuin C., Yamamoto R., Suemune S., Kozai K., Tanne K., Aubin J.E., and Maeda N. Mineralized tissue cells are a principal source of FGF23. Bone 40 (2007) 1565-1573
103. Zhang X., Ibrahimi O.A., Olsen S.K., Umemori H., Mohammadi M., and Ornitz D.M. Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J. Biol. Chem. 281 (2006) 15694-15700